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Summary
Background In low-income and middle-income countries, invasive mechanical ventilation is often not available for 
children at risk of death from respiratory failure. We aimed to determine if continuous positive airway pressure 
(CPAP), a form of non-invasive ventilation, decreases all-cause mortality in children with undifferentiated respiratory 
distress in Ghana.
Methods This open-label, cluster, crossover trial was done in two Ghanaian non-tertiary hospitals where invasive 
mechanical ventilation is not routinely available. Eligible participants were children aged from 1 month to 5 years 
with a respiratory rate of more than 50 breaths per min in children 1–12 months old, or more than 40 breaths per min 
in children older than 12 months, and use of accessory muscles or nasal flaring. CPAP machines were allocated to 
one hospital during each study block, while the other hospital served as the control site. The initial intervention site 
was randomly chosen using a coin toss. 5 cm of water pressure was delivered via CPAP nasal prongs. The primary 
outcome measure was all-cause mortality rate at 2 weeks after enrolment in patients for whom data were available 
after 2 weeks. We also did post-hoc regression analysis and subgroup analysis of children by malaria status, oxygen 
saturation, and age. This study is registered with ClinicalTrials.gov, number NCT01839474.
Findings Between Jan 20, 2014, and Dec 5, 2015, 2200 children were enrolled: 1025 at the intervention site and 1175 at 
the control site. Final analysis included 1021 patients in the CPAP group and 1160 patients in the control group. 
2 weeks after enrolment, 26 (3%) of 1021 patients in the CPAP group, and 44 (4%) of 1160 patients in the control group, 
had died (relative risk [RR] of mortality 0·67, 95% CI 0·42–1·08; p=0·11). In children younger than 1 year, all-cause 
mortality was ten (3%) of 374 patients in the CPAP group, and 24 (7%) of 359 patients in the control group (RR 0·40, 
0·19–0·82; p=0·01). After adjustment for study site, time, and clinically important variables, the odds ratio for 2-week 
mortality in the CPAP group versus the control group was 0·4 in children aged up to 6 months, 0·5 for children aged 
12 months, 0·7 for children aged 24 months, and 1·0 for those aged 36 months. 28 patients (3%) in the CPAP group 
and 24 patients (2%) in the control group had CPAP-related adverse events, such as vomiting, aspiration, and nasal, 
skin, or eye trauma. No serious adverse events were observed.
Interpretation In the unadjusted analysis the use of CPAP did not decrease all-cause 2-week mortality in children 
1 month to 5 years of age with undifferentiated respiratory distress. After adjustment for study site, time, and clinically 
important variables, 2-week mortality in the CPAP group versus the control group was significantly decreased in 
children 1 year of age and younger. CPAP is safe and improves respiratory rate in a non-tertiary setting in a lower-
middle-income country.
Funding General Electric Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.
Introduction
Pneumonia, sepsis, and severe malaria kill more than 
2 million children younger than 5 years every year.1,2 
These treatable illnesses can present as undifferentiated 
acute respiratory distress that can progress to respiratory 
failure. Most of these deaths occur in low-income 
and middle-income countries, where diagnostic and 
therapeutic interventions are often severely scarce.1,3,4 
Further, because of physician shortages, patients are 
often treated by non-physician clinicians. Interventions 
to improve patient outcomes in low-income and 
middle-income countries will have maximum effect if 
they do not depend on sophisticated diagnostic tests and 
if they can be initiated and managed by non-physician 
health-care providers.
Continuous positive airway pressure (CPAP) can 
improve survival in premature neonates with respiratory 
distress syndrome in low-income and middle-income 
countries.5–7 Results from two studies8,9 suggest that CPAP 
could improve survival beyond the neonatal period in 
children with primary pulmonary disease, although 
neither study was large and both were done in academic 
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medical centres. In a previous randomised clinical trial,10 
we showed the feasibility and safety of nurse-initiated 
CPAP for children with respiratory distress in non-
tertiary hospitals in Ghana, and found that CPAP lowered 
respiratory rate in this population. CPAP technology is 
less expensive (approximately US$400 per CPAP 
machine and $32 per nasal interface),11,12 has lower 
complication rates, and requires less technical skill than 
invasive mechanical ventilation, making it an attractive 
option in resource-poor countries.13–15
In resource-poor regions of the world, laboratory and 
radiographic diagnostic tests are not routinely available, 
and nurses initiate medical interventions without close 
oversight from a physician. In these settings, it is not 
feasible to reliably identify which children with 
respiratory distress have primary pulmonary processes 
(pneumonia, pulmonary oedema) and which have non-
pulmonary processes (sepsis, severe malaria, metabolic 
acidosis). Thus, we aimed to determine if nurse-initiated 
CPAP decreases all-cause 2-week mortality in children 
with undifferentiated respiratory distress.
Methods
Study design
This study was an open-label, prospective, cluster, 
crossover trial that was done at two non-tertiary hospitals 
in Ghana. The aim was to determine whether the 
application of CPAP decreased all-cause 2-week mortality 
in children aged from 1 month to 5 years who presented 
with undifferentiated acute respiratory distress.
Study sites were two non-tertiary hospitals (Mampong 
District Hospital and Kintampo Municipal Hospital), 
where invasive mechanical ventilation was not routinely 
available, and nurses initiated and managed care with 
once or twice daily physician rounds. The two study 
hospitals were located 135 km apart. Each hospital 
employed between two and four physicians, had four or 
five paediatric beds in the emergency ward, and served a 
catchment area with approximately 100 000 people. Both 
hospitals had equipment to conduct full blood count, 
malaria microscopy, and plain radiographs, but inc-
onsistent availability of electricity, reagents, and tech-
nicians limited their use. Neither hospital routinely did 
bacterial cultures, respiratory viral panels, blood gases, 
chemistry panels, chest radiographs, or echo cardiograms. 
Both sites had hospital-wide generators that were used 
during prolonged power outages if fuel was available. 
The study provided smaller generators to each emergency 
ward to provide continuous power. Generators were 
available at both the control and the intervention site 
throughout the study period and were donated to the 
sites at the end of the study.
The study protocol was approved by the Columbia 
University Medical Center Institutional Review Board 
Research in context
Evidence before this study
We searched PubMed and Cochrane databases with the search 
terms “child” OR “pediatric” OR “infant” AND any combination 
of “bubble CPAP” OR “bubble continuous positive airway 
pressure” OR “nasal CPAP”. We also searched these databases 
with the terms “developing country” or “low or middle income 
country”, and “efficacy” OR “survival” OR “treatment outcomes”. 
The reports we identified that were published before our study 
were either based in neonatal intensive care units focusing on 
the neonatal period, or did not look at mortality as an outcome 
measure. Before the start of this trial, we found no studies 
evaluating the effect of continuous positive airway 
pressure (CPAP) on mortality in children aged from 1 month to 
5 years, presenting with undifferentiated acute respiratory 
distress in non-tertiary hospitals in a low-income or 
middle-income country. In a previously published randomised 
clinical trial, we showed feasibility and safety of 
nurse-administered CPAP for children with respiratory distress 
in four non-tertiary hospitals in Ghana. That study showed that 
CPAP lowers respiratory rate at 1 h, but it was not powered to 
detect a difference in mortality. This study was an open-label 
cluster crossover trial done in two non-tertiary hospitals in 
Ghana. The aim of the study was to determine whether the use 
of CPAP decreases all-cause 2-week mortality in children aged 
1 month up to 5 years old, presenting with undifferentiated 
acute respiratory distress.
Added value of this study
We aimed to evaluate the effectiveness of CPAP in a setting 
where nurses care for patients with limited physician 
oversight, and where diagnostic tests such as radiographs, 
microbiological cultures, and blood gas analyses are not 
routinely done. In this context, CPAP was associated with 
improved respiratory rate and decreased mortality in children 
with undifferentiated respiratory distress, driven by improved 
survival in children less than 1 year old. No serious adverse 
events were observed. Our findings demonstrate CPAP is 
effective and safe to use in district level hospitals by emergency 
ward nurses who work much of the day without direct 
supervision by a physician.
Implications of all the available evidence
Our findings show the effect of CPAP on all-cause mortality in 
children with respiratory distress treated outside the tertiary 
care setting. Results from two smaller studies in academic 
centres in Bangladesh and Malawi showed that CPAP was 
associated with improved survival in children with primary 
pulmonary diseases. These findings, taken collectively, support 
the use of non-invasive ventilation for children presenting with 
acute respiratory distress in low-resource settings. Our findings 
are a step forward in codifying best practices for treating 
children with undifferentiated respiratory distress in 
resource-limited settings.
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and local institutional review boards at the Kwame 
Nkrumah University of Science and Technology and 
Ghana Health Services, and by the leadership of each 
hospital. The Ghana Food and Drug Authority provided 
regulatory oversight.
CPAP was delivered according to a previously 
published protocol.10
Participants
All children presenting to the hospitals’ emergency 
departments with fast breathing were screened for study 
eligibility. Inclusion criteria were age 1 month to 5 years, 
respiratory rate of more than 50 breaths per min in 
children 1–12 months old or more than 40 breaths per 
min in children older than 12 months, and use of 
accessory muscles or nasal flaring. Exclusion criteria 
included skin breakdown around the nose or mouth, 
facial trauma, inability to protect the airway, persistent 
emesis, unresponsiveness or coma, poor respiratory 
effort requiring positive pressure ventilation, known or 
suspected pneumothorax, asthma, upper airway 
obstruction, or cardiac instability (systolic blood pressure 
less than the fifth percentile for age). Research staff were 
available 24 h a day, 7 days a week to enrol patients. CPAP 
was applied and managed by the existing hospital staff 
nurses, who were trained by study investigators. Written 
documentation of informed consent was obtained after 
the participants’ guardians reviewed the consent form 
written in English, or had it translated verbally into their 
spoken language.
Randomisation and masking
CPAP machines were allocated to one hospital 
(intervention site) for each study block, while the other 
hospital served as the control site. The initial intervention 
site was randomly chosen with a coin toss. CPAP was 
available at Mampong Hospital for the first 6 months, 
then at Kintampo Hospital for the subsequent 12 months, 
and then back to Mampong for the final 6 months. Each 
site thus served as an intervention site and control site 
for 12 months, covering every calendar month to control 
for seasonal variability. There was no masking.
Procedures
CPAP was delivered with the DeVilbiss IntelliPAP CPAP 
machine (Somerset, PA, USA) using a previously 
published protocol.10 5 cm of water pressure was delivered 
regardless of age, oxygen saturation, or clinical 
presentation. Seven CPAP machines were provided to 
each site and this was a sufficient number throughout 
the study. Three sizes of single-use Hudson RCI nasal 
prongs (Durham, NC, USA) were available as the 
interface. Size selection was determined by best fit in the 
nares and obtaining a complete seal. Delivered pressure 
was locked at 5 cm of water and confirmed by observing 
bubbles in the expiratory bottle of the closed system. Wall 
oxygen or concentrators were used to administer the 
minimal amount of oxygen needed to maintain an 
oxygen saturation of at least 92% as measured by pulse 
oximetry, either through the CPAP circuit or via a non-
rebreather facemask in the control group. Because the 
enrolled patients might have been suffering from severe 
anaemia or severe sepsis, and they were critically ill with 
very fast breathing, we used 92% as the cutoff to avoid 
being too close to the steep part of the oxygen dissociation 
curve. Since physicians are not usually present in the 
emergency ward at the study hospitals, emergency ward 
nurses were responsible for the initiation and 
management of CPAP. CPAP was continued until the 
patient had a normal respiratory rate for their age (at 
which time it was immediately removed), was unable to 
tolerate the device, developed a nasal or facial skin injury, 
transferred to another facility, or died. The treating 
clinician could elect to remove CPAP at any time. 
Patients were treated per local care and physicians’ 
orders. Every 6 months, the local research staff received 
refresher training on the use of CPAP and the 
management of critically ill children.
Respiratory rate, oxygen saturation, heart rate, blood 
pressure, and temperature were recorded at baseline, 4 h, 
8 h, 12 h, and 24 h. Study staff were trained to count 
respiratory rate for 60 s, either continuously or in two 30 s 
blocks using a stopwatch or the second hand of a 
timepiece, according to WHO recom mendations.16 
General Electric Dinamap V100 (Fairfield, CT, USA) 
automated patient monitors were provided by the study 
group to measure oxygen saturation, heart rate, non-
invasive blood pressure, and axillary temperature.
Haemoglobin was measured with each hospital’s 
existing full blood count machine. Plasmodium falciparum 
malaria was tested using rapid antigen detection with 
either Standard Diagnostics HRP-II (Gyeonggi-do, 
South Korea) or Premier Medical Corporation HRP-2 
(Gujarat, India). Adverse events were recorded on case 
report forms, which included specific prompts to report 
any vomiting; aspiration; or nasal, skin, or eye trauma. 
A hospital visit, home visit, or phone call was used to 
document the status of the patient from 2 weeks after 
enrolment. Data from the paper case report forms were 
transferred via double data entry to an electronic 
Microsoft Access database.
Outcomes
The primary outcome was all-cause mortality 2 weeks 
after enrolment. Secondary outcomes were change in 
respiratory rate at 24 h, rate of adverse events, and 
proportion of patients requiring supplemental oxygen 
for oxygen saturations lower than 92%. Safety analysis 
included all adverse events and serious adverse events 
for both groups. 
Statistical analysis
A sample size of 906 participants in each group was 
calculated to detect a 3% absolute reduction in mortality 
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rate (from 7% to 4%), assuming a power of 0·8 and 
significance level of 0·05. Sample size estimation and 
analysis were applied at the individual level. Assuming a 
5% loss to follow-up at 2 weeks, we planned to enrol 
950 subjects in each arm; 26 patients a month at each 
study site over 3 years. Enrolment of participants 
progressed faster than anticipated; with approval from 
the data and safety monitoring board and all regulatory 
boards, the total sample size was increased to 2200 to 
allow for 2 complete calendar years of enrolment, to 
account for seasonal variation. Analyses were done in 
patients for whom data were available. We assessed 
categorical variables using a χ² test. We analysed 
continuous variables using a t-test and Mann-Whitney 
U test, which gave similar results for all comparisons. 
We also did post-hoc regression analysis and subgroup 
analysis of children by malaria status, oxygen saturation, 
and age. The analysis based on age subgroups was not 
written in the original IRB protocol or ClinicalTrials.gov. 
We developed a more complete data analysis plan before 
enrolment ended and study analysis started, including 
the subgroup analysis. We chose the conservative 
approach of describing it as post-hoc in this Article.
The outcome variable was binary (dead or alive at 
2 weeks), therefore we fitted a multivariate logistic 
regression model with the predictors study arm, study 
site, study month, age, respiratory rate, and oxygen 
saturation. Since there were only two study sites, we 
included this variable as a fixed effect to adjust by site. A 
quadratic term for study month was considered to allow 
non-linear association with the outcome. Interaction 
effects of age with study arm, and age with study site, 
were also included.
The results reported here are based on complete cases. 
Multiple imputation was used for missing values (n=512, 
haemoglobin; n=18, rapid malaria; n=1, oxygen saturation), 
and the results were similar to the results obtained using 
the observed data. We used the multi variate imputation by 
chained equations method, which considers fully con-
ditional specifications, for multiple imputation. This 
method is based on an iterative Markov Chain Monte 
Carlo method. At each iteration, a variable is chosen from 
the variable list in the order provided and a regression 
model is fitted using all the other variables in the list as 
predictors. The missing values in the dependent variable 
are then imputed. The method continues until the 
maximum number of iterations is reached. The results 
were similar to the ones obtained with the available data. 
In this paper we only present the results using the original 
data. We used SAS version 9.4 for the analyses.
The data and safety monitoring board reviewed study 
data at 10%, 25%, and 50% of planned enrolment, and 
did an interim analysis at 50% enrolment (early stopping 
boundary; p≤0·003). A local safety monitoring team, 
consisting of three Ghanaian paediatricians, conducted 
15 site visits over the study period to ensure study 
compliance. The study is registered with ClinicalTrials.
gov, number NCT01839474.
CPAP (n=1025) Control (n=1175)
Sex
Female 455 (44%) 515 (44%)
Male 570 (56%) 660 (56%)
Age (months) 16·7 (8·8–27·9) 18·3 (10·1–30·2)
Weight (kg) 9·6 (7·4–11) 9·6 (7·5–12)
Respiratory rate (breaths 
per min)
56 (50–62) 55 (48–62)
Oxygen saturation
Oxygen saturation (%)* 98% (96–99) 98% (97–100)
Patients with oxygen 
saturation <92%
74 (7%) 69 (6%)
Heart rate (beats per min) 153 (140–169) 152 (138–166)
Temperature (°C) 37·6 (36·8–38·5) 37·6 (36·8–38·4)
Systolic blood pressure 
(mm Hg)
101 (95–110) 102 (96–115)
Median haemoglobin (g/dL)† 8·5 (6·4–9·9) 8·0 (6·1–9·6)
Malaria positive by rapid 
antigen detection‡
 689/1015 (68%) 856/1148 (75%)
Data are n (%) or median (IQR). All continuous variables were found to be 
non-normally distributed when performing the Kolmogorov-Smirnov test, with 
p values approximately 0·0001. The medians and IQRs are reported for 
continuous variables and the relative frequency shown for the categorical 
variables. CPAP=continuous positive airway pressure. *One patient in the control 
group did not have an oxygen saturation recorded.†512 patients did not have a 
haemoglobin test performed (n=179 for CPAP; n=333 for control). 
‡18 participants had invalid or no malaria rapid diagnostic test results (n=6 for 
CPAP; n=12 for control)
Table 1: Baseline characteristics of the intention-to-treat population
Figure 1: Trial profile
CPAP=continuous positive airway pressure. *CPAP was available at Mampong Hospital for the first 6 months, then 
at Kintampo Hospital for the next 12 months, and then back at Mampong for the final 6 months. All patients 
enrolled at the intervention site received CPAP, and no patients at the control site received CPAP. †Participant was 
younger than 1 month old after enrolment, removed from final analyses.
2200 enrolled
2486 patients assessed for eligibility
1222 Kintampo Hospital
1264 Mampong Hospital
286 excluded
246 ineligible
40 declined to participate
1175 enrolled at control site*
515 Kintampo
660 Mampong
15 excluded
2 withdrew consent 
9 lost to 2-week follow-up 
1 lost case report form
3 enrolled but did not meet age criteria†
1160 included in primary analysis 1021 included in primary analysis 
1025 enrolled at CPAP site*
653 Kintampo
372 Mampong
4 excluded
3 withdrew consent
1 lost to 2-week follow-up
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Role of the funding source
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Between Jan 20, 2014 and Dec 5, 2015, 2486 children were 
screened. 246 were found to be ineligible, and 40 did not 
have parental approval to participate. 2200 participants 
were enrolled, 1025 in the CPAP group, and 1175 in the 
control group. The parents of three patients withdrew 
consent and one patient was lost to follow-up in the 
CPAP group. In the control group, two patients withdrew 
consent, nine were lost to follow-up, one case report 
form was lost, and three children were less than 1 month 
of age. 2181 participants were included in the final 
analysis (1021 in the CPAP group and 1160 in the control 
group; figure 1).
Compared with children in the control group, children 
in the CPAP group were younger and had similar 
respiratory rates and haemoglobin levels. Children in the 
CPAP group also had a lower prevalence of positive 
malaria rapid antigen detection (table 1).
All patients enrolled at a CPAP site received the 
intervention, and none in the control group were 
managed with CPAP. The median duration of CPAP use 
was 12 h (range 0·08–98, IQR 7·2–19·8). CPAP was 
discontinued for the following reasons: improved 
respiratory status (n=953 [93%] of 1021 patients), not 
tolerating the device (n=47 [5%] of 1021 patients), death 
(n=16 [1·6%] of 1021 patients), nasal skin injury 
(n=3 [0·3%] of 1021 patients), transferred to another 
facility (n=1 [0·1%] of 1021 patients), and loss of electricity 
with no generator use for unknown reasons (n=1 [0·1%] 
of 1021 patients).
The analysis of the primary endpoint did not show a 
significant difference between study groups (table 2). Of 
the 2181 patients, 1958 (90%) were alive at 2 weeks at the 
hospital or home visit, and 153 (7%) were reported alive 
by a relative or community member. A total of 70 deaths 
Dead (n=70) Alive (n=2111) p value
Study group
Control 44/1160 (4%) 1116/1160 (96%) 0·11
CPAP 26/1021 (3%) 995/1021 (97%) ··
Study site
Mampong 31/1022 (3%) 991/1022 (97%) 0·72
Kintampo 39/1159 (3%) 1120/1159 (97%) ··
Median month of 
study enrolment*
10·5 (5–19) 15 (9–19) 0·003
Sex
Female 33/965 (3%) 932/965 (97%) 0·63
Male 37/1216 (3%) 1179/1216 (97%) ··
Age (months) 12·5 (4·4–29·6) 17·7 (9·6–28·9) 0·015
Weight (kg) 7·8 (5–10) 9·8 (7·5–11·5) <0·0001
Respiratory rate 
(breaths per min)
62 (54–70) 56 (49–62) <0·0001
Oxygen saturation 
(%)†
96 (90–98) 98 (97–99) <0·0001
Heart rate (beats per 
min)
163 (138–175) 152 (138–167) 0·019
Temperature (°C) 37·5 (36·7–38·4) 37·6 (36·8–38·4) 0·71
Systolic blood 
pressure (mm Hg)
102 (93–113) 102 (95–112) 0·498
Haemoglobin (g/dL)‡ 8·2 (5·6–10·3) 8·3 (6·2–9·8) 0·97
Malaria rapid diagnostic test§
Positive 42/1546 (3%) 1504/1546 (97%) 0·047
Negative 27/617 (4%) 590/617 (96%) ··
Data are n (%) or median (IQR). We used the Mann-Whitney U test for all 
continuous variables since they were all not normally distributed based on 
Kolmogorov Smirnov test. χ² test was used for categorical variables. The medians 
and IQRs are shown for continuous variables and the absolute and relative 
frequencies are given for categorical variables. CPAP=continuous positive airway 
pressure.*The “month of study enrolment” variable orders the 1 year study period 
into 24 months; for patients enrolled in the first month of the study the value of 
the variable equals 1, for those enrolled in the 10th month the value of the 
variable equals 10. †One patient (alive) did not have an oxygen saturation 
recorded. ‡512 patients did not have a haemoglobin test (n=12 dead; 
n=500 alive). §18 patients had invalid or no malaria rapid diagnostic test  
results (n=1 dead; n=17 alive). 
Table 2: Univariate analysis showing the distribution of study outcome 
by baseline characteristics
Odds ratio (95% CI)
1 month 0·37 (0·16–0·87)
2 months 0·38 (0·17–0·86)
3 months 0·39 (0·18–0·86)
6 months 0·43 (0·21–0·86)
12 months 0·50 (0·28–0·89)
18 months 0·59 (0·35–1·00)
24 months 0·70 (0·40–1·24)
36 months 0·97 (0·41–2.33)
48 months 1·36 (0·38–4·88)
Table 3: Participant age (months) and adjusted odds ratios for all-cause 
mortality 
Exp(Est)* p value
Study group (CPAP vs control) 0·36 0·023
Study site  
(Kintampo vs Mampong)
0·34 0·016
Month of study enrolment 0·72 0·0003
Month of study enrolment squared 1·01 0·0012
Respiratory rate (breaths per min) 1·04 <0·0001
Oxygen saturation (%) 0·93 <0·0001
Age (months) 0·96 0·065
Age × study arm† 1·03 0·17
Age × study site† 1·05 0·0295
We fitted a logistic multivariate regression model. CPAP=continuous positive airway 
pressure. *Exp(Est)=exponentiated parameter estimate. †Interaction effects. 
Table 4: Multivariate model for all-cause mortality
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were observed (44 [4%] of 1160 patients in the control 
group and 26 [3%] of 1021 patients in the CPAP group; 
RR of mortality 0·67, 95% CI 0·42–1·08; p=0·11). The 
most common reported causes of death were malaria (21 
deaths in the control group, ten deaths in the CPAP 
group), pneumonia (19 deaths in the control group, 
12 deaths in the CPAP group), sepsis (18 deaths in the 
control group, seven deaths in the CPAP group), and 
anaemia (15 deaths in the control group, six deaths in the 
CPAP group), with most patients having multiple 
diagnoses. 66 deaths occurred in the hospital and four 
occurred after discharge from the emergency ward.
In the additional analysis by age group, more children 
younger than 1 year had died in the control group (24 [7%] 
of 359 patients) than in the CPAP group (ten [3%] of 
374 patients; RR 0·40, 95% CI 0·19–0·82; p=0·010). In 
children aged between 1 and 5 years, there was no 
significant difference in mortality (RR 0·992, 0·51–1·93; 
p=0·977). After adjusting for study site, study month, 
age, respiratory rate, oxygen saturation, and interactions 
of age on study site and study arm, the odds ratio (OR) 
for 2-week mortality in the CPAP group over control 
group was 0·4 in children aged up to 6 months, 0·5 for 
children 12 months of age, 0·7 for children 24 months of 
age, and 1·0 for children 36 months of age (table 3, 
table 4). Subgroup analyses by malaria status, and oxygen 
saturation less than 90% or 92%, showed no significant 
difference in mortality at 2 weeks between the CPAP and 
control groups.
In children at all ages, respiratory rate was significantly 
lower in the CPAP group at 4 h, 8 h, 12 h, and 24 h 
(p<0·001 at each timepoint; figure 2). All patients were 
monitored for vomiting, aspiration, and nasal, skin and 
eye trauma. In the CPAP group, 28 (3%) of 1021 patients 
had one or more of these events reported during the 
study period, compared with 24 (2%) of 1160 patients in 
the control group (p=0·30; table 5). Nasal trauma was 
Figure 2: Mean respiratory rates over time by study group
Mean respiratory rates are in breaths per min. All SEM values are less than 0·4. (A) All children. All p values are p<0·0001. 
(B) Children younger than 1 year old. All p values are p<0·0001. (C) Children aged 1 year and older. All p values are 
p<0·0001. CPAP=continuous positive airway pressure. 
Number at risk
Control
CPAP
0 4 8 12 16 20 24
1025
1172
1016
1154
1013
1146
1007
1140
··
··
··
··
··
··
··
··
··
··
··
··
1002
1133
30
35
40
45
50
55
60
65
Re
sp
ira
to
ry
 ra
te
A
Number at risk
Control
CPAP
0 4 8 12 16 20 24
362
375
356
372
349
370
347
369
343
368
30
35
40
45
50
55
60
65
Re
sp
ira
to
ry
 ra
te
B
Number at risk
Control
CPAP
0 4 8 12 16 20 24
810
650
798
644
797
643
793
638
790
634
Time (h)
30
35
40
45
50
55
60
65
Re
sp
ira
to
ry
 ra
te
C
Control
CCAP
CPAP 
(n=1021)
Control 
(n=1160)
p value*
CPAP-related adverse events 28 (3%) 24 (2%) 0·30
Vomiting 20 (2%) 21 (2%) ··
Nasal trauma 5 (1%) 1 (<1%) ··
Skin trauma 3 (0·3%) 1 (<1%) ··
Aspiration 0 (0%) 1 (<1%) ··
Eye trauma 0 (0%) 0 (0%) ··
Other reported adverse events† 70 (7%) 85 (7%) 0·7
Fever 21 (2%) 45 (4%) ··
Cough 21 (2%) 29 (3%) ··
Diarrhoea or gastrointestinal 
complaints
21 (2%) 14 (1%) ··
Rash 3 (<1%) 8 (1%) ··
Skin or mucous membrane 
complaints
1 (<1%) 7 (1%) ··
Respiratory distress or dyspnoea 1 (<1%) 4 (<1%) ··
Rhinitis 3 (<1%) 1 (<1%) ··
Swelling (ear, neck, hand, foot) 2 (<1%) 2 (<1%) ··
Seizure 3 (<1%) 0 (0%) ··
Anaemia or malaria 1 (<1%) 2 (<1%) ··
Other‡ 2 (<1%) 3 (<1%) ··
Data are n (%). Vomiting, aspiration, nasal, and skin or eye trauma were recorded 
as present or absent on the case report form, and other adverse events were 
written in. CPAP=continuous positive airway pressure. *Based on a χ² test that 
included all 2181 participants. †79 events in 70 participants in the CPAP group, 
and 115 events in 85 participants in the control group. ‡CPAP group: child cannot 
stand on left leg or child has high blood pressure; control group: excessive crying, 
tongue felt hot, and child was weak; child not able to talk after disease; or child 
could not open her eye when she woke up.
Table 5: Reported adverse events by study group
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more common in the CPAP group (n=5) than in the 
control group (n=1), without significance. No incidents of 
known or suspected pneumothorax or other serious 
adverse events related to CPAP were reported.
We found that mortality was associated with younger 
age, lower bodyweight, higher respiratory rate and lower 
oxygen saturation. Survival was positively associated with 
study month: the later in the study a patient was enrolled, 
the more likely he or she was to survive.
Discussion
There was no difference in all-cause mortality at 2 weeks. 
Nurse-initiated CPAP decreased respiratory rate in 
children younger than 5 years and was associated with a 
decrease in mortality in children less than 1 year old who 
presented to non-tertiary hospitals in a lower-middle-
income country with undifferentiated respiratory 
distress. No serious adverse events attributed to CPAP 
were noted.
Results from previous studies8,9 have shown the 
effectiveness of CPAP in selected populations of children 
with well characterised primary pulmonary diseases who 
are managed at teaching hospitals in low-income and 
middle-income countries. By contrast, our study took 
place at non-tertiary hospitals where invasive mechanical 
ventilation is not routinely available, and diagnostic 
evaluations are limited in availability. Scarce access to 
reliable diagnostic testing is documented throughout 
sub-Saharan Africa,3,4 highlighting the importance of 
identifying interventions that are effective in un-
differentiated populations. Our findings suggest that 
the use of CPAP in young children with respiratory 
insufficiency is appropriate in other parts of the 
developing world, where diagnostic capabilities are 
similarly limited.
Potential mechanisms for improved outcomes in 
children with primary pulmonary diseases such as 
pneumonia and pulmonary oedema who receive CPAP 
include recruitment of atelectatic alveoli, increased 
functional residual capacity,17 improved lung compliance, 
decreased shunting and redistribution of lung water 
away from gas exchange membranes. Furthermore, 
CPAP might decrease afterload, improve cardiac output,18 
and unload the work of the diaphragm, contributing to 
improved outcomes in children with sepsis, severe 
malaria, and metabolic acidosis. The effectiveness of 
CPAP does not seem to be solely related to improved 
oxygen saturation. Only 6·5% of our study patients had 
oxygen saturations less than 92% at presentation, and 
the CPAP group did not have higher oxygen saturation 
than the control group at any time point. Further research 
is required to definitively determine if CPAP is associated 
with improved survival in children with specific non-
primary pulmonary processes such as severe malaria, 
sepsis, or metabolic acidosis to ensure appropriate 
prioritisation of the technology in resource-limited 
settings.
Our study is unique in that CPAP was initiated and 
managed by emergency ward nurses who work much of 
the day without direct supervision by a physician. The 
WHO recommends redistributing health-care tasks to 
less highly trained individuals, when possible, to make 
more efficient use of limited human resources,19 as well 
as shifting the management of chest indrawing 
pneumonia to the community level.20 With a nurse to 
doctor ratio of 8:1 in many African nations,21 successful 
training of nurses to effectively and safely apply CPAP 
will be crucial for its proliferation in non-tertiary hospitals. 
Our study included twice-yearly CPAP refresher training 
for nurses caring for study patients. Further work is 
needed to determine how best to scale up and maintain 
training of non-physician providers in the use of CPAP.22
We found that mortality was associated with younger 
age, lower bodyweight, higher respiratory rate and lower 
oxygen saturation, which is consistent with other 
published data.8,9,13,14,23 Survival was positively associated 
with study month: the later in the study a patient was 
enrolled, the more likely he or she was to survive. We 
speculate that this improved survival over time was 
related to incremental improvements in clinical care as 
the study progressed. This improvement could be related 
to periodic training sessions, increasing comfort with 
patient monitoring, or variation of disease severity 
between study years.
CPAP significantly lowered respiratory rate throughout 
the 24-h monitoring period in all age groups, showing a 
prolonged physiological benefit. Despite this fact, a 
decrease in mortality was only seen among children 
younger than 1 year old. Younger patients might have 
different disease processes, a possibility that was not 
explored fully in this study due to limits in diagnostic 
evaluations. Further, the nasal prongs may have provided 
a better seal in younger patients. Differences in end 
expiratory lung volume, functional residual capacity, dead 
space and upper airway collapsibility may make younger 
patients more amenable to the benefits of CPAP 
compared to older patients.
This trial has several limitations. A pure, randomised 
control study design was not used, with allocation by site 
rather than by patient, and analyses were applied at the 
patient level. More patients in the CPAP group were 
enrolled from Kintampo than Mampong. The chosen 
study design was selected for simplicity and to maximise 
compliance with allocation, but it is susceptible to 
concealment and enrolment bias. Precise diagnoses of 
study participants are not known, secondary to limited 
capacity of the hospital laboratories. However, the study is 
generalisable in low-income and middle-income 
countries where diagnostics are very often scarce.3,4 In 
powering the study, we estimated a baseline mortality 
of 7%, but the control group had a mortality of only 3·8%. 
Our incorrect assumption of the baseline mortality might 
have lead to the study being underpowered. Our 
respiratory rate definitions for fast breathing were similar 
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